Company: BIAF
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024163
Chunk: 64

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 7
Chunk 64
---
 treatment offers a 95% 10-year survival
rate as compared to the current overall 5-year survival rate of 26%. and the patient’s prognosis, according to a NEJM study. Physicians
have reported numerous patient case studies in which CyPath® Lung was the critical clinical decision maker including instances
in which cancer was detected in Stage 1A when existing treatments can be curative. On July 29, 2025, the Company released details of a
case study in which Stage 1A invasive mucinous adenocarcinoma was detected by CyPath® Lung after imaging and a competitive
serum test were indeterminate.

On
July 23, 2025, the Company announced that CyPath® Lung identified a Stage 1A neuroendocrine tumor in the patient’s
lung after PET scan, bronchoscopies and a serum tumor marker test suggested the pulmonary nodule was non-cancerous inflammation.

On
July 9, 2025, the Company released details of a complex clinical case in which CyPath® Lung identified Stage 1A adenocarcinoma
lung cancer in a patient whose PET imaging and risk model probability indicated a low risk of malignancy. In each case, use of our test
was the determining factor that led to a biopsy and treatment.

These
most recent case studies follow release on May 8, 2025, of the report “CyPath® Lung in Practice” authored
by Gordon Downie, MD, PhD, then Director of the Titus Regional Hospital Lung Nodule Clinic and Interventional Pulmonology, in which he
reported on case studies including an 85-year-old patient who averted biopsy after CyPath® Lung was negative for cancer,
persuading the patient to wait for three months when a new CT showed the nodules had disappeared. The paper also reported on a patient
who was previously treated for lung cancer and had a small nodule in the opposing lung. The CyPath® Lung was positive
for cancer and a biopsy confirmed a second primary lung cancer for which the patient is being treated. In a third case study, CyPath®
Lung helped identify a hidden recurrence of breast cancer after a routine CT detected a small pulmonary nodule.

Appointment
of Chief Medical Officer

On
June 15, 2025, Dr. Gordon Downie was appointed Chief Medical Officer. Dr. Downie brings more than three decades of experience in pulmonary
medicine, clinical research, medical innovation,